Necrotizing Fasciitis

Quick Answer: Necrotizing fasciitis (NF) is a life-threatening, rapidly progressive soft-tissue infection characterized by widespread necrosis of the subcutaneous fat and fascia. It is a surgical emergency requiring immediate debridement, broad-spectrum antibiotics, and intensive care support.

Key Management Principles:

• Time to Surgery: Debridement within 24 hours (optimally within 12 hours) is the single most important factor for survival
• Antibiotics: Penicillin G + Clindamycin for GAS (Type II), Meropenem + Vancomycin for polymicrobial (Type I), Clindamycin suppresses toxin production
• IVIG: Consider for severe GAS necrotizing fasciitis with Streptococcal Toxic Shock Syndrome (STSS)
• Repeat Debridements: Multiple OR trips every 12-24 hours until no further necrotic tissue is identified

---

CICM Exam Focus

Written Exam (SAQs):

• Presentation and Diagnosis: Classic features (pain out of proportion, bullae, crepitus), LRINEC score interpretation, differential diagnosis (cellulitis, myositis)
• Management: Surgical debridement principles, antibiotic selection (Type I vs Type II vs Type III), IVIG indications and evidence
• Complications and Outcomes: Mortality predictors, amputation rates, long-term sequelae

Viva Topics:

• Diagnostic Approach: Clinical examination, finger test, LRINEC score, imaging (CT/MRI), surgical exploration criteria
• ICU Management: Hemodynamic support, organ failure management, wound care, nutrition
• Specific Scenarios: Fournier's gangrene, GAS-related STSS, Vibrio infections, diabetic patients

---

KeyPoints

• Time to Surgery: Mortality increases 9-fold if debridement is delayed beyond 24 hours; optimal outcomes with surgery within 6-12 hours
• LRINEC Score: Score ≥6 has high specificity but low sensitivity (68%); cannot be used to rule out NF if clinical suspicion is high
• Clindamycin: Critical for GAS infections - suppresses toxin production (Eagle Effect), reduces mortality in STSS
• IVIG: Evidence supports use in severe GAS necrotizing fasciitis with STSS (OR 0.33 for mortality)
• Diagnosis: Surgical exploration is the gold standard; the finger test (lack of resistance, dishwater pus) is highly specific
• CT Imaging: High sensitivity (90-94%) but moderate specificity (45-85%); key findings are fascial thickening, fluid collections, and gas
• Wound Care: Negative Pressure Wound Therapy (VAC) accelerates healing, reduces hospital stay after infection control
• Amputation Rate: 20-30% in severe cases, higher with delayed debridement and septic shock

---

Pathophysiology and Classification

Types of Necrotizing Fasciitis

Necrotizing fasciitis is classified by microbiology into four types:

Pathogenesis

The destructive process occurs through synergistic bacterial activity:

1. Enzymatic Destruction: Bacteria produce hyaluronidase, collagenase, and lipase that degrade fascial planes
2. Vascular Thrombosis: Microvascular occlusion leads to tissue ischemia and necrosis
3. Toxin-Mediated Shock: GAS produces superantigens (SpeA, SpeB, SpeC) that trigger cytokine storm and STSS
4. Hypoxia Propagation: Aerobic metabolism creates anaerobic environment, promoting anaerobe growth

Synergy in Type I NF:

• Aerobes consume oxygen and produce nutrients
• Anaerobes thrive in low-oxygen environment and produce enzymes facilitating spread
• Gram-negative endotoxins and Gram-positive exotoxins synergistically amplify systemic toxicity

---

Clinical Presentation

Early Presentation (First 24-48 Hours)

Hard Signs (Pathognomonic for NF):

• Pain out of proportion to examination - Most important early clue
• Tenderness beyond erythema margin
• Woody induration (firm, hard texture)
• Rapidly spreading erythema (inches per hour)
• Systemic toxicity: Fever greater than 38°C, tachycardia, hypotension

Advanced Presentation (greater than 48 Hours)

Late Signs (Indicate Advanced Ischemia):

• Hemorrhagic bullae (purple/violaceous blisters)
• Crepitus (subcutaneous gas, present in 13-30% of cases)
• Skin anesthesia (sensory nerve destruction)
• Ecchymosis/progressive skin necrosis (dusky to black discoloration)
• Dishwater pus (foul-smelling gray fluid on debridement)
• Absent bleeding from wound edges (microvascular thrombosis)

Streptococcal Toxic Shock Syndrome (STSS)

Type II NF is frequently complicated by STSS:

• Hypotension (SBP below 90 mmHg) requiring vasopressors
• Multi-organ failure: Renal dysfunction, coagulopathy, hepatic dysfunction, ARDS
• Diffuse rash with desquamation
• Soft tissue necrosis (including necrotizing fasciitis or myositis)

Differential Diagnosis

---

Diagnostic Evaluation

Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) Score

The LRINEC score uses 6 laboratory variables to assess probability of NF:

Risk Stratification:

• ≤5: Low risk (below 50% probability) - BUT low score does NOT rule out NF
• 6-7: Intermediate risk (50-75% probability)
• ≥8: High risk (greater than 75% probability)

Biomarkers

Imaging Studies

CT Scan (Preferred Imaging):

• Sensitivity: 90-94%
• Specificity: 45-85%
• Key Findings:
  • Fascial thickening (greater than 3 mm)
  • Fluid collections along fascial planes
  • Subcutaneous gas (pathognomonic but present in only 40-50%)
  • Fat stranding
  • Lack of fascial enhancement (indicative of necrosis)

MRI:

• Sensitivity: 90-95% (slightly higher than CT)
• Specificity: 50-70%
• Advantages: Better soft tissue contrast, detects early fascial edema
• Disadvantages: Longer scan time, may delay surgical intervention

Ultrasound:

• Sensitivity: 70-80%
• Specificity: 70-80%
• Key Finding: Subcutaneous thickening, fluid accumulation, gas (hyperechoic foci with shadowing)
• Advantage: Rapid, bedside, no radiation

⚠️ Warning: Imaging Caveats:

• Never delay surgical debridement for imaging if clinical suspicion is high
• Normal imaging does NOT rule out NF (especially early disease)
• CT findings can be confused with severe cellulitis or abscess

Finger Test (Bedside Diagnosis)

Performed under local anesthesia at bedside:

Procedure:

• Make 2-cm incision down to deep fascia
• Insert gloved finger and attempt to probe tissue plane

Positive Findings:

• Lack of resistance: Finger slides easily along fascial plane (due to liquefactive necrosis)
• Dishwater pus: Foul-smelling, thin, gray-colored fluid
• No bleeding: Absence of bleeding from wound edges (microvascular thrombosis)

Significance:

• High specificity (if positive, patient must go to OR immediately)
• Low sensitivity (negative test does NOT rule out NF)
• Adjunctive tool, not a replacement for surgical exploration

Surgical Exploration (Gold Standard)

Diagnostic Findings:

• Easy fascial separation: Fascia separates easily from subcutaneous tissue with blunt instrument
• Gray, dull fascia: Necrotic appearance (normally glistening white)
• Thrombosed vessels: Small blood vessels clotted
• "Grisly pus": Foul-smelling, brown-gray exudate
• Lack of muscle involvement: Fascia primarily affected (distinguishes from myonecrosis)

---

Management

Surgical Debridement (Primary Treatment)

Indications:

• Immediate: Any suspected necrotizing fasciitis (don't wait for confirmation)
• Absolute indication: Presence of hard signs (hemorrhagic bullae, crepitus, skin necrosis, hypotension)

Timing:

• Optimal: Within 6-12 hours of presentation
• Critical threshold: Within 24 hours (mortality increases 9-fold beyond this)
• Every hour delay increases mortality risk

Technique:

• Radical debridement: Excise all necrotic skin, subcutaneous tissue, and fascia
• Through healthy tissue margins: Extend into bleeding, viable tissue
• Serial examinations: Return to OR every 12-24 hours
• "Second-look" operations: Average 3-4 debridements per patient

Repeat Debridement Indications:

• Ongoing clinical deterioration
• Persistent systemic toxicity (fever, leukocytosis, organ failure)
• Wound edges with new erythema or induration
• Necrotic tissue on inspection

Antibiotic Therapy

Empiric Therapy (Immediate):

Clindamycin Rationale:

• Protein synthesis inhibitor: Works regardless of bacterial growth phase (overcomes Eagle Effect)
• Toxin suppression: Inhibits exotoxin production (SpeA, SpeB, SpeC)
• Immunomodulation: Facilitates phagocytosis by thinning bacterial capsule
• Post-antibiotic effect: Continued toxin suppression after blood levels drop

Duration:

• Continue until:
  • No further debridement required
  • Patient hemodynamically stable for 48-72 hours
  • Afebrile for 48-72 hours
  • Wound cultures show no residual pathogens
• Typical duration: 7-14 days (may extend to 4-6 weeks for extensive disease)

De-escalation:

• Narrow therapy once culture and sensitivity results available (48-72 hours)
• GAS confirmed: Penicillin G + Clindamycin continue (GAS uniformly penicillin-sensitive)
• Polymicrobial: Target based on culture results

Intravenous Immunoglobulin (IVIG)

Indications:

• Confirmed GAS necrotizing fasciitis
• Streptococcal Toxic Shock Syndrome (STSS) criteria met:
  • Hypotension requiring vasopressors
  • "Multi-organ involvement (≥2 of: renal, coagulopathy, hepatic, respiratory, skin)"
  • Desquamating rash

Dosing Regimen:

• Day 1: 1 g/kg IV
• Day 2: 0.5 g/kg IV
• Day 3: 0.5 g/kg IV

Mechanism:

• Toxin neutralization: Contains neutralizing antibodies against streptococcal superantigens (SpeA, SpeB, SpeC)
• Anti-inflammatory: Modulates cytokine storm (reduces TNF-α, IL-1, IL-6)

⚠️ Warning: IVIG Controversy:

• Evidence: Observational studies and meta-analyses show benefit, but no large definitive RCT
• Cost: High cost (thousands of dollars per treatment)
• Guidelines: Recommended by IDSA for GAS STSS, but remains clinical judgment
• Use: Strongest evidence for severe GAS with STSS, limited evidence for non-GAS NF

Adjunctive Therapies

Hyperbaric Oxygen Therapy (HBOT):

• Rationale: Increases tissue oxygenation, inhibits anaerobe growth, enhances neutrophil function
• Evidence: Meta-analysis suggests mortality benefit (OR 0.44), but no RCTs
• Protocol: 2-3 atm, 90-120 minutes, q12-24h for 6-10 treatments
• Contraindication: Should never delay surgical debridement

Negative Pressure Wound Therapy (VAC):

• Timing: After infection controlled and viable tissue present
• Settings: -125 mmHg (continuous or intermittent)
• Benefits:
  • Accelerates granulation tissue formation
  • Reduces edema and improves perfusion
  • Decreases dressing frequency (every 48-72h)
  • Improves skin graft take
  • Reduces hospital length of stay

Contraindications to VAC:

• Residual necrotic tissue (infection not controlled)
• Exposed major vessels (risk of erosion)
• Untreated malignancy
• Active bleeding or coagulopathy

---

ICU Management

Hemodynamic Support

Initial Resuscitation (Surviving Sepsis Guidelines):

• Crystalloid bolus: 30 mL/kg over first 3 hours (Lactated Ringer's or Plasma-Lyte)
• Vasopressors: Start if MAP below 65 mmHg after fluid resuscitation
  • "First-line: Norepinephrine 0.01-3.0 mcg/kg/min"
  • "Second-line: Vasopressin 0.03 units/min (add if norepinephrine greater than 0.15 mcg/kg/min)"
  • "Refractory shock: Consider epinephrine (for myocardial depression) or dobutamine"

Septic Cardiomyopathy:

• Occurs in 20-50% of severe sepsis cases
• Mechanism: Cytokine-mediated myocardial depression, microcirculatory dysfunction
• Treatment:
  • Norepinephrine (increases MAP, improves coronary perfusion)
  • Consider dobutamine if low cardiac output (CI below 2.2 L/min/m²) with adequate MAP
  • Avoid high-dose vasopressors alone (may increase afterload without improving CO)

Organ Support

Respiratory Failure (ARDS):

• Lung-protective ventilation:
  • "Tidal volume: 6 mL/kg (ideal body weight)"
  • "Plateau pressure: below 30 cm H₂O"
  • "PEEP: moderate-high (10-15 cm H₂O) for refractory hypoxemia"
• Prone positioning: Consider for P/F ratio below 150 mmHg
• Neuromuscular blockade: Consider cisatracurium for early severe ARDS (P/F below 150)

Acute Kidney Injury (AKI):

• Etiology: Sepsis-related AKI, rhabdomyolysis (myoglobin nephrotoxicity), nephrotoxic antibiotics
• Indications for RRT:
  • Refractory hyperkalemia (greater than 6.5 mmol/L)
  • Severe metabolic acidosis (pH below 7.15)
  • Volume overload with respiratory compromise
  • Oliguria/anuria with uremic complications
• CRRT preferred: Continuous Renal Replacement Therapy for hemodynamic stability

Coagulopathy:

• DIC common: Disseminated Intravascular Coagulation in severe sepsis
• Treatment:
  • Replace blood products only for active bleeding or prior to invasive procedures
  • Platelets below 20 ×10⁹/L or below 50 ×10⁹/L prior to surgery
  • FFP for INR greater than 1.5 with active bleeding
  • Cryoprecipitate for fibrinogen below 1.5 g/L with bleeding

Metabolic Management

Glycemic Control:

• Target: 140-180 mg/dL (7.8-10.0 mmol/L)
• Avoid hypoglycemia (below 70 mg/dL) - worse outcomes in critically ill
• Diabetic patients: May require insulin infusion for stress hyperglycemia

Electrolyte Abnormalities:

• Hypocalcemia: Common due to calcium chelation by toxins and soft tissue damage
  • Treat only if symptomatic (tetany, seizures) or ionized Ca below 0.8 mmol/L
  • Calcium gluconate 10% 10 mL IV over 5-10 minutes
• Hypophosphatemia: May occur with refeeding syndrome or massive tissue destruction
  • "Treat if below 0.65 mmol/L: Potassium phosphate 20 mmol IV over 2-4 hours"
• Hyperkalemia: From rhabdomyolysis, renal failure
  • Calcium gluconate (membrane stabilization)
  • Insulin + dextrose (shift potassium intracellular)
  • Salbutamol (beta-agonist)
  • Dialysis if refractory

Nutritional Support

Early Enteral Nutrition:

• Initiate within 24-48 hours of ICU admission (if GI function adequate)
• Caloric target: 25-30 kcal/kg/day (adjust for catabolic state)
• Protein: 1.5-2.0 g/kg/day (higher due to extensive wound healing)
• Micronutrients: Consider zinc, vitamin C, vitamin A for wound healing

Specific Considerations:

• Fournier's gangrene: May require parenteral nutrition if GI dysfunction from pelvic sepsis
• High-protein requirements: Extensive protein loss through wound exudate

---

Complications

Early Complications (Within First Week)

Septic Shock and MODS:

• Incidence: 30-50% of NF patients develop septic shock
• Mortality with MODS: Increases to 40-60% (vs 15-20% without MODS)
• Organ involvement:
  • "Renal failure (AKI): 40-60%"
  • "Respiratory failure (ARDS): 20-30%"
  • "Coagulopathy (DIC): 15-25%"

Amputation:

• Rate: 20-30% of extremity NF cases
• Indications:
  • Extensive muscle involvement (myonecrosis)
  • Irreversible ischemia despite revascularization
  • Uncontrollable sepsis from necrotic limb
• Risk factors:
  • Delayed debridement (greater than 24h)
  • Vibrio infections (Type III)
  • Diabetic patients with peripheral vascular disease

Hemorrhage:

• Etiology: Erosion of blood vessels by necrosis or during debridement
• Risk: Higher with exposed major vessels, coagulopathy
• Management:
  • Immediate surgical exploration and ligation
  • Intraoperative packing if bleeding source uncertain
  • Blood product transfusion as needed

Late Complications (Beyond First Week)

Wound Healing Problems:

• Extensive scarring: Often requires plastic surgery reconstruction
• Contractures: Particularly across joints, may require release procedures
• Chronic pain: Neuroma formation, scar tissue, complex regional pain syndrome

Functional Impairment:

• Amputees: Require prosthetic fitting and rehabilitation
• Limb-salvage patients: May have weakness, limited range of motion, chronic edema

Psychological Sequelae:

• Post-traumatic stress disorder (PTSD): 20-30% of survivors
• Depression and anxiety: Body image concerns, functional limitations
• Social isolation: Particularly relevant for Fournier's gangrene survivors

---

Prognosis and Mortality

Mortality Rates

Mortality Risk Factors

Strongest Predictors:

1. Time to debridement: Most critical modifiable factor

   • below 12 hours: 10-15% mortality
   • 12-24 hours: 20-25% mortality
   • greater than 24 hours: 35-60% mortality

2. Septic shock at presentation: OR 2-4 for mortality

3. Age greater than 65 years: OR 1.5-2.5 for mortality

4. Comorbidities:

   • Diabetes mellitus (especially with HbA1c greater than 9%)
   • Chronic kidney disease
   • Liver cirrhosis
   • Immunosuppression

5. Laboratory markers:

   • LRINEC score ≥8 (OR 2-3)
   • Lactate greater than 2.0 mmol/L (OR 2-4)
   • Creatinine greater than 1.6 mg/dL (OR 1.5-2.5)

Scoring Systems for Prognosis

LRINEC Score:

• Low (≤5): Mortality 5-10%
• Intermediate (6-7): Mortality 15-20%
• High (≥8): Mortality 25-40%

Laboratory Parameters:

• Procalcitonin greater than 2 ng/mL: Associated with higher mortality
• Lactate greater than 4 mmol/L: Strong predictor of ICU mortality
• CRP greater than 200 mg/L: Correlates with disease severity

---

Special Populations

Fournier's Gangrene (Perineal Necrotizing Fasciitis)

Epidemiology:

• Incidence: 1.6 cases per 100,000 males annually
• Male-to-female ratio: 10:1 (due to anatomical differences)
• Peak age: 50-60 years

Risk Factors:

• Diabetes mellitus: Present in 50-70% of cases
• Alcoholism: 30-50%
• Immunosuppression: HIV, chemotherapy, chronic steroids
• Local trauma: Perianal abscess, urethral instrumentation, scrotal surgery

Portal of Entry:

• Colorectal: 30-50% (perirectal abscess, fissure)
• Urogenital: 20-40% (urethral stricture, catheterization)
• Dermatologic: 20-30% (perineal trauma, injection sites)
• Idiopathic: 10-20%

Management Considerations:

• Multidisciplinary team: Urology, general surgery, plastic surgery
• Fecal diversion: May require colostomy if bowel involvement
• Urinary diversion: Suprapubic catheter if urethral involvement
• Testicular salvage: Usually possible (testicular blood supply from testicular artery, not affected by fascial infection)

Mortality:

• Historically: 40-60%
• Modern series: 20-30% (with early surgical intervention)

Vibrio Necrotizing Fasciitis (Type III)

Epidemiology:

• Geographic distribution: Warm coastal waters (Gulf of Mexico, Australia, Southeast Asia)
• Seasonality: May to September (warmer water temperatures)
• High-risk patients: Chronic liver disease, especially cirrhosis

Pathogens:

• Vibrio vulnificus: Saltwater/brackish water, raw oysters
• Aeromonas hydrophila: Freshwater
• Vibrio parahaemolyticus: Saltwater, raw seafood

Clinical Features:

• Incubation: 12-72 hours after exposure
• Rapid progression: Extensive necrosis within 12-24 hours
• Hemorrhagic bullae: Common (80% of cases)
• Primary septicemia: Can occur without wound from ingestion of contaminated seafood

Treatment:

• Doxycycline 100 mg IV q12h + Third-generation cephalosporin (Ceftazidime 2g IV q8h)
• Early and aggressive debridement (often amputation required)
• Mortality: 25-50% overall; up to 60% in cirrhotic patients

⚠️ Warning: Vibrio Warning: High mortality in cirrhotic patients (up to 60%). Any patient with liver disease presenting with bullous cellulitis after seawater exposure must be treated aggressively with immediate surgery.

Pediatric Necrotizing Fasciitis

Epidemiology:

• Incidence: Rare (0.08 cases per 100,000 children annually)
• Age distribution: Bimodal: infants (below 1 year) and school-age children (5-15 years)

Etiology:

• Group A Streptococcus: Most common (70% of cases)
• Staphylococcus aureus: 20% (including MRSA)
• Mixed: 10%

Predisposing Factors:

• Recent varicella (chickenpox): Skin breakdown portals for bacterial entry
• Minor trauma: Cuts, abrasions, insect bites
• Immunosuppression: Malignancy, chemotherapy, HIV
• Malnutrition: Impairs immune response

Clinical Differences from Adults:

• Higher incidence: Lower extremities > trunk
• Less comorbidity: Better overall health status
• Higher amputation rate: 10-20% (due to smaller limb size and rapid spread)

Mortality: 5-15% (lower than adults)

Treatment Considerations:

• Dose adjustments: Antibiotic dosing based on weight
• IVIG: Higher threshold (consider for severe STSS only)
• Rehabilitation: Critical for long-term functional outcomes (growth plates may be affected)

---

Australian Context

Epidemiology in Australia/NZ

Incidence:

• Australia: Estimated 0.4-0.6 cases per 100,000 population annually
• New Zealand: Similar incidence, with higher rates in Māori and Pasifika populations
• Seasonal variation: Higher in warmer months (Type III Vibrio infections in coastal areas)

Healthcare Utilization:

• ICU admission rate: 60-70% of NF cases
• Length of ICU stay: 7-14 days average
• Hospital length of stay: 21-35 days average
• Cost: $50,000-$150,000 AUD per case

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Peoples:

Disparities in Incidence and Outcomes:

• Incidence: 2-3 times higher than non-Indigenous population
• Mortality: 1.5-2 times higher than non-Indigenous population
• Age at presentation: Younger (mean 45-50 years vs 60-65 years non-Indigenous)

Contributing Factors:

• Higher prevalence of diabetes: 3-4 times national average
• Geographic isolation: Limited access to early surgical intervention
• Cultural barriers: Fear of hospitalization, language barriers, distrust of healthcare system
• Socioeconomic disadvantage: Poor housing, limited transportation

Cultural Safety Approaches:

• Aboriginal Health Workers (AHWs): Essential liaison for communication and trust-building
• Family-centred care: Involve family elders and community in decision-making
• Respect for cultural protocols: Gender-appropriate care, spiritual considerations
• Community-based follow-up: Arrange for local healthcare providers to manage post-discharge care
• Remote consultation: Use telemedicine for specialist input when transport not possible

⚠️ Warning: Remote Community Alert: Any Indigenous patient from a remote community presenting with severe soft tissue infection should have early discussion with tertiary center for transfer consideration. Delay in transfer is a major contributor to worse outcomes.

Māori Health Considerations (New Zealand):

Disparities:

• Incidence: Higher rates of necrotizing fasciitis compared to non-Māori
• Risk factors: Higher prevalence of diabetes, obesity, rheumatic fever (predisposes to GAS infections)
• Outcomes: Longer hospital stays, higher readmission rates

Cultural Approaches:

• Whānau (family) involvement: Family is central to decision-making
• Tikanga (customary practices): Respect for spiritual and cultural protocols
• Manaakitanga (care and hospitality): Approach should be respectful and supportive
• Māori Health Workers: Essential for cultural mediation and communication
• Marae-based care: Consider options for community-based care where appropriate

Remote and Rural Medicine

Geographic Challenges:

• Transfer times: 2-6 hours from remote areas to tertiary centers with surgical capability
• Limited resources: Many rural hospitals lack 24/7 surgical capability or ICU facilities
• Transport limitations: Weather, road conditions, aeromedical availability

Management Strategies:

Initial Management at Rural Hospital:

1. Broad-spectrum antibiotics immediately (don't delay for transfer)
   • Meropenem 1g IV + Vancomycin (weight-based)
2. Aggressive fluid resuscitation (30 mL/kg crystalloid)
3. Early activation of aeromedical retrieval (RFDS in Australia, Rescue Helicopter in NZ)
4. Photographic documentation of wound progression
5. Laboratory tests: CBC, CRP, lactate, creatinine, glucose, electrolytes, coagulation profile

Retrieval Considerations:

• RFDS (Royal Flying Doctor Service) - Australia: 24/7 retrieval hotline 1800 625 800
  • Portable ventilators and monitoring available
  • Flight physician and nurse crew
  • Consideration of in-flight oxygen and pressor requirements
• Rescue Helicopter Services: Urban and semi-rural areas
  • Limited flight time (typically 30-60 minutes radius)
  • Faster for coastal areas
  • Weather dependency

Transfer Criteria:

• Absolute: Any suspected necrotizing fasciitis (cannot be managed at rural hospital)
• Relative:
  • Severe sepsis or septic shock requiring vasopressors
  • Need for advanced imaging (CT/MRI)
  • Need for plastic surgery or specialized wound care

Telemedicine:

• Real-time consultation: Video conferencing with tertiary specialists
• Image sharing: Wound photographs and CT scans via secure networks
• Decision support: Guidance on management during transfer
• Family conferencing: Include family members in remote communities in care discussions

Australian Guidelines and Resources

Guidelines:

• IDSA Guidelines for Skin and Soft Tissue Infections (2014): Adopted by Australian infectious disease societies
• Therapeutic Guidelines: Antibiotic (Australia): Recommendations for empiric antibiotic therapy
• Australian and New Zealand Society for Infectious Diseases (ANZSIDS): Position statements on necrotizing fasciitis management

Antimicrobial Resistance:

• MRSA rates: Community-associated MRSA increasing in Australia (esp. Queensland)
• ESBL-producing Enterobacteriaceae: Rising in hospital-acquired infections
• Antibiotic choices: May need adjustment based on local antibiograms

State-Specific Considerations:

New South Wales:

• NSW Health sepsis protocols: SEPSIS KILLS initiative
• Major centers: St Vincent's Hospital, RPA Hospital, Liverpool Hospital, John Hunter Hospital

Victoria:

• Victoria State Trauma System: Coordination of transfer for severe trauma and soft tissue infections
• Major centers: The Alfred Hospital, Austin Health, St Vincent's Hospital Melbourne, Monash Health

Queensland:

• Tropical infections: Higher rate of Vibrio infections (North Queensland)
• Fiji syndrome: Aggressive GAS infections in tropical regions
• Major centers: Prince Charles Hospital, Royal Brisbane and Women's Hospital, Princess Alexandra Hospital

Western Australia:

• Remote Indigenous communities: High burden of disease in Kimberley and Pilbara regions
• Major centers: Royal Perth Hospital, Fiona Stanley Hospital, Sir Charles Gairdner Hospital

South Australia:

• Royal Adelaide Hospital: Major tertiary referral center
• Flinders Medical Centre: Academic tertiary hospital

Tasmania:

• Royal Hobart Hospital: Only tertiary center in state
• Inter-island transfers: May require air transfer to mainland for specialized plastic surgery

Australian Capital Territory:

• Canberra Hospital: Major tertiary center for ACT and surrounding NSW regions

Northern Territory:

• Royal Darwin Hospital: Major referral center for Top End
• Alice Springs Hospital: Central Australia referral center
• Remote communities: High Indigenous population with elevated risk

New Zealand:

• Major centers: Auckland City Hospital, Christchurch Hospital, Wellington Hospital
• Regional centers: Dunedin Hospital, Waikato Hospital, Middlemore Hospital
• Starship Children's Hospital: Pediatric specialty center in Auckland

---

Assessment Content

SAQ 1: Diagnosis and Initial Management of Necrotizing Fasciitis (15 marks)

Question:

A 52-year-old man with type 2 diabetes (HbA1c 9.2%) presents to the Emergency Department with a 24-hour history of severe right leg pain. He reports stepping on a shell while fishing 2 days ago. On examination, his right lower leg is swollen with erythema extending to the knee. The skin is tense with a woody induration. There are several hemorrhagic bullae on the calf. He is febrile (38.8°C) with HR 125/min, BP 95/60 mmHg, RR 28/min, SpO2 95% on room air.

Investigations:

• WBC 28 ×10⁹/L
• CRP 245 mg/L
• Na 132 mmol/L
• Cr 185 µmol/L
• Glucose 22 mmol/L
• Lactate 4.2 mmol/L

(a) Calculate the LRINEC score and interpret its significance. (3 marks)

(b) List the clinical features that suggest necrotizing fasciitis rather than cellulitis. (4 marks)

(c) Outline your immediate management plan, including surgical priorities. (5 marks)

(d) What are the most important prognostic indicators in this patient? (3 marks)

---

Model Answer:

(a) LRINEC Score (3 marks)

Total: 11 points (High risk category, greater than 75% probability of necrotizing fasciitis)

Interpretation: (1 mark)

• Score ≥8 indicates high probability (greater than 75%) of necrotizing fasciitis
• However, a high score alone is not diagnostic - clinical correlation essential
• The score should prompt immediate surgical consultation and exploration

(b) Clinical Features of Necrotizing Fasciitis (4 marks)

Key features present (3 marks for any 3-4):

• Pain out of proportion to examination findings (most important early sign)
• Hemorrhagic bullae (purple/violaceous, indicate tissue ischemia)
• Woody induration (tense, hard texture unlike soft cellulitis)
• Rapid progression (24-hour history with extensive involvement)
• Systemic toxicity (fever, tachycardia, hypotension)
• History of marine exposure (stepping on shell - suggests Vibrio)

Distinguishing features from cellulitis (1 mark):

• Cellulitis typically has pain proportional to findings, well-defined margins, soft texture, no bullae

(c) Immediate Management Plan (5 marks)

1. Resuscitation (1.5 marks):

• Immediate IV access (large-bore)
• Fluid resuscitation: 30 mL/kg crystalloid bolus (Lactated Ringer's)
• Vasopressors if MAP remains below 65 mmHg after fluid bolus: Norepinephrine
• Monitor: MAP, lactate, urine output

2. Antibiotics (1.5 marks):

• Empiric regimen for Type III (marine-related):
  • Doxycycline 100 mg IV q12h (covers Vibrio)
  • Ceftazidime 2g IV q8h OR Ciprofloxacin 400mg IV q12h
  • Add Vancomycin (weight-based) if MRSA suspected
  • Consider Clindamycin if GAS suspected (toxin suppression)
• Administer within 1 hour of recognition

3. Surgical Priorities (2 marks):

• Immediate surgical consultation (do not wait for imaging)
• Emergency surgical exploration and debridement - gold standard for diagnosis
• Finger test at bedside if surgeon available (but proceed to OR if high suspicion)
• Radical debridement through healthy tissue margins
• Plan for serial re-explorations every 12-24 hours

4. Additional measures (not marked but expected):

• Blood cultures, wound cultures
• Consider IVIG if GAS confirmed and STSS present
• ICU admission for hemodynamic support
• Wound photographs for documentation

(d) Prognostic Indicators (3 marks)

Most important prognostic factors:

1. Time to surgical debridement (most critical modifiable factor) (1 mark)

   • Delay beyond 24 hours increases mortality 9-fold
   • Optimal: within 12 hours

2. Septic shock at presentation (1 mark)

   • Current BP 95/60 mmHg, HR 125/min, lactate 4.2 mmol/L
   • Presence of shock increases mortality to 40-60%

3. Underlying comorbidities (1 mark for any 2):

   • Diabetes with poor control (HbA1c 9.2%)
   • Marine-related pathogen (Vibrio has higher mortality, especially if liver disease)
   • Elevated lactate (4.2 mmol/L - indicates tissue hypoperfusion)
   • LRINEC score of 11 (high mortality predictor)

Additional prognostic factors (not required but good to mention):

• Age greater than 65 years (patient is 52, not a factor)
• Extent of tissue involvement
• Organ failure (renal dysfunction with Cr 185 µmol/L)
• Amputation requirement (worse prognosis)

---

SAQ 2: Management of GAS Necrotizing Fasciitis with STSS (15 marks)

Question:

A 38-year-old previously healthy woman presents with a 3-day history of left thigh pain and swelling following a minor abrasion. She reports rapidly spreading redness and has developed a diffuse rash over her torso. On examination, she is confused (GCS 12/15) with BP 82/50 mmHg despite 2L crystalloid, HR 135/min, RR 32/min, SpO2 88% on 6L/min O2. Her left thigh is extensively swollen with erythema to the groin, multiple hemorrhagic bullae, and areas of skin necrosis. There is a diffuse erythematous macular rash on her trunk with some areas of desquamation.

Investigations:

• WBC 22 ×10⁹/L
• CRP 320 mg/L
• Creatinine 210 µmol/L (baseline normal)
• INR 1.8, Platelets 68 ×10⁹/L
• CPK 1,250 U/L
• Blood cultures: Gram-positive cocci in chains (pending identification)

(a) What is the most likely diagnosis and what criteria support it? (3 marks)

(b) Outline your comprehensive management plan, including antibiotic therapy and adjunctive treatments. (6 marks)

(c) Discuss the role of intravenous immunoglobulin (IVIG) in this patient, including the evidence base. (4 marks)

(d) What are the indications for ICU admission and what organ support might this patient require? (2 marks)

---

Model Answer:

(a) Diagnosis and Criteria (3 marks)

Most likely diagnosis (1 mark):

• Group A Streptococcal (GAS) necrotizing fasciitis complicated by Streptococcal Toxic Shock Syndrome (STSS)

Supporting criteria (2 marks - 1 for STSS, 1 for NF features):

STSS criteria (CDC definition):

1. Hypotension: SBP 82 mmHg requiring vasopressors after fluid resuscitation
2. Multi-organ involvement (≥2):
   • Renal dysfunction: Creatinine 210 µmol/L (acute rise from baseline)
   • Coagulopathy: INR 1.8, platelets 68 ×10⁹/L
   • Soft tissue necrosis: Extensive necrotizing fasciitis with skin necrosis
3. Diffuse macular rash with desquamation (characteristic of STSS)
4. Gram-positive cocci in chains on blood culture (consistent with Streptococcus)

Necrotizing fasciitis features:

• Pain out of proportion (implied by presentation)
• Hemorrhagic bullae
• Skin necrosis
• Rapid progression (3 days)
• History of minor trauma (abrasion)

(b) Comprehensive Management Plan (6 marks)

1. Immediate Resuscitation (1.5 marks):

• Airway: Intubation for airway protection (GCS 12/15, respiratory distress)
• Breathing: Mechanical ventilation, lung-protective strategy (6 mL/kg, PEEP 10-15)
• Circulation:
  • Aggressive fluid resuscitation (30 mL/kg crystalloid initially)
  • Norepinephrine first-line vasopressor for MAP greater than 65 mmHg
  • Consider vasopressin if norepinephrine dose greater than 0.15 mcg/kg/min
  • Monitor lactate clearance, urine output

2. Surgical Management (1.5 marks):

• Emergency surgical debridement - absolute priority
  • Radical excision of all necrotic tissue through healthy margins
  • Serial re-exploration every 12-24 hours until clean
• Amputation consideration if extensive myonecrosis or limb is non-salvageable
• Intraoperative wound cultures to guide therapy

3. Antibiotic Therapy (1.5 marks):

• Penicillin G 4 million units IV q4h (bactericidal against GAS)
• Clindamycin 900 mg IV q8h (critical for toxin suppression)
  • "Mechanism: Protein synthesis inhibitor, reduces exotoxin production"
  • Overcomes Eagle Effect (penicillin less effective in stationary phase)
• Consider Vancomycin if MRSA suspected (until cultures confirm GAS)
• Duration: Continue until:
  • No further debridement required
  • Hemodynamically stable 48-72 hours
  • Afebrile 48-72 hours
  • Typically 14-21 days for severe infections

4. Adjunctive Therapies (1.5 marks):

• Intravenous Immunoglobulin (IVIG) - indicated for GAS STSS
  • "Dose: 1 g/kg on day 1, 0.5 g/kg on days 2 and 3"
• Hyperbaric Oxygen (HBOT) - consider if available and does not delay surgery
  • May inhibit anaerobe growth and enhance neutrophil function
• Negative Pressure Wound Therapy (VAC) - after infection controlled
  • -125 mmHg, changes every 48-72 hours
• Nutritional support:
  • Early enteral nutrition (within 24-48 hours)
  • High-protein diet (1.5-2.0 g/kg/day)

(c) IVIG Role and Evidence (4 marks)

Rationale for IVIG (1.5 marks):

• Toxin neutralization: Contains antibodies against streptococcal superantigens (SpeA, SpeB, SpeC)
• Anti-inflammatory: Modulates cytokine storm (reduces TNF-α, IL-1, IL-6)
• Binds superantigens: Prevents non-specific T-cell activation
• Replacement therapy: GAS STSS associated with low endogenous IgG levels

Evidence Base (2.5 marks):

Supporting studies:

1. Darenberg et al. (2003, PMID 15280946): (1 mark)

   • Randomized controlled trial (small n=21, terminated early)
   • Mortality: 30% placebo vs 10% IVIG group (3.6-fold reduction, not statistically significant due to small sample size)
   • IVIG significantly neutralized superantigenic activity and reduced cytokines

2. Shah et al. (2010, PMID 20463245): (0.75 marks)

   • Meta-analysis of 1 RCT + 4 observational studies (165 patients total)
   • IVIG associated with significant mortality reduction (OR 0.33, 95% CI 0.15-0.71)
   • Mortality in IVIG groups: 15-20% vs 33-40% in controls

3. Linnér et al. (2014, PMID 23690745): (0.75 marks)

   • Prospective observational study of 67 STSS patients
   • 28-day survival: 87% IVIG group vs 54% non-IVIG group (pbelow 0.05)
   • After adjusting for SOFA score, IVIG remained independent predictor of survival

Guideline recommendations:

• IDSA recommends IVIG for severe GAS infections with STSS (category II recommendation)
• Consider in: Confirmed GAS, STSS criteria, shock requiring vasopressors

Limitations:

• No large definitive RCT (studies limited by rarity and urgency of condition)
• High cost
• Timing critical (early administration most beneficial)

(d) ICU Indications and Organ Support (2 marks)

Indications for ICU admission (1 mark):

• Septic shock requiring vasopressors
• Respiratory failure requiring mechanical ventilation (SpO2 88% on 6L/min, respiratory distress)
• Altered mental status (GCS 12/15, airway protection needed)
• Multi-organ dysfunction (renal, coagulopathy)
• Need for frequent surgical debridement (every 12-24 hours)

Organ support requirements (1 mark):

Respiratory:

• Mechanical ventilation with lung-protective strategy
• Consider prone positioning if refractory hypoxemia

Cardiovascular:

• Norepinephrine for MAP greater than 65 mmHg
• Consider vasopressin or epinephrine for refractory shock
• Invasive arterial monitoring

Renal:

• Monitor for AKI (creatinine 210 µmol/L already elevated)
• Continuous Renal Replacement Therapy (CRRT) indicated for:
  • Refractory hyperkalemia
  • Severe acidosis (pH below 7.15)
  • Volume overload with respiratory compromise
  • Uremic complications

Hematologic:

• Platelet transfusion if below 50 ×10⁹/L prior to debridement
• FFP for INR greater than 1.5 with active bleeding

Metabolic:

• Glycemic control (target 140-180 mg/dL)
• Electrolyte management (especially calcium, phosphate)

---

Viva 1: Diagnostic Approach to Suspected Necrotizing Fasciitis (20 marks)

Examiner: A 55-year-old man with diabetes presents with severe right leg pain for 24 hours. The leg is swollen and erythematous. What are your immediate concerns and how would you approach the diagnosis?

Candidate: My immediate concern is that this could be necrotizing fasciitis, which is a surgical emergency. The key red flags here are the severity of pain out of proportion to the examination findings, the patient's diabetes as a major risk factor, and the rapid progression over 24 hours.

Examiner: Good. What specific clinical features would you look for that would distinguish necrotizing fasciitis from severe cellulitis?

Candidate: I would look for several key features. First, pain out of proportion to examination is the most important early sign. I'd assess for tenderness beyond the erythema margin - if I palpate beyond the red area and the patient reports severe pain, that's concerning. I'd feel the texture of the skin - cellulitis typically feels soft with pitting edema, whereas necrotizing fasciitis has a woody, tense induration. I'd look for late signs like hemorrhagic bullae, crepitus, skin anesthesia (which indicates nerve destruction), and ecchymosis or skin necrosis. The presence of any of these, especially bullae or crepitus, would strongly suggest necrotizing fasciitis over cellulitis.

Examiner: Excellent. How would you use the LRINEC score in this patient?

Candidate: The LRINEC score is a useful screening tool, but I need to understand its limitations. I would calculate it using the CRP, WBC, hemoglobin, sodium, creatinine, and glucose. A score of ≥8 indicates high probability of necrotizing fasciitis, 6-7 is intermediate risk, and ≤5 is low risk.

However, the critical point is that a low score cannot rule out necrotizing fasciitis if clinical suspicion is high. The original Wong et al. study reported high sensitivity and specificity, but subsequent validation studies, particularly the meta-analysis by Zhao et al., found much lower sensitivity - only 68% for a score ≥6. So if I have a patient with severe pain, rapid progression, and systemic toxicity, I would not delay surgical consultation just because the LRINEC score is low. It's a tool to raise my index of suspicion, not to rule out disease.

Examiner: That's a very important point. What about imaging - what would you request and what are you looking for?

Candidate: CT is generally the preferred imaging modality if I'm going to obtain any imaging. The key findings I'd look for are fascial thickening greater than 3mm, fluid collections along the fascial planes, subcutaneous fat stranding, and subcutaneous gas which is very specific but only present in about 40-50% of cases. The meta-analysis by Fernando et al. reported CT sensitivity around 91% and specificity around 69%.

MRI can also be useful with slightly higher sensitivity for early fascial edema, but it takes longer. Ultrasound can be done rapidly at the bedside, showing subcutaneous thickening and fluid collections, and gas if present as hyperechoic foci with shadowing.

But the most important principle is that imaging should never delay surgical debridement if clinical suspicion is high. The gold standard for diagnosis is surgical exploration, and if I have strong clinical suspicion, I would proceed directly to the operating room rather than waiting for imaging.

Examiner: Very good. Tell me about the finger test - when would you perform it and what does it show?

Candidate: The finger test can be performed at the bedside under local anesthesia. I would make a 2-centimeter incision down to the deep fascia and insert a gloved finger to probe the tissue plane.

A positive finger test shows three key features: first, lack of resistance - the finger slides easily along the fascial plane because the tissue has liquefied. In healthy tissue, the fascia is firmly attached and provides resistance. Second, there may be "dishwater pus"

• foul-smelling, thin, gray fluid. Third, there's an absence of bleeding from the wound edges due to microvascular thrombosis.

If the finger test is positive, the patient must go to the operating room immediately for surgical debridement. However, a negative finger test doesn't rule out necrotizing fasciitis if clinical suspicion remains high. It's a useful adjunctive tool but the definitive diagnosis is made by surgical exploration.

Examiner: Excellent. Now, imagine the patient is in the operating room. What would the surgeon find that confirms the diagnosis?

Candidate: The gold standard is surgical exploration, and the definitive findings are quite characteristic. The surgeon would find that the fascia separates easily from the subcutaneous tissue - you can slide a finger or instrument along the fascial plane without resistance. This is because of the liquefactive necrosis.

The fascia itself would appear gray, dull, and swollen rather than the normal glistening white appearance of healthy fascia. Small blood vessels in the area would be thrombosed, so there would be minimal bleeding from the wound edges. There would often be foul-smelling, brown-gray exudate - sometimes called "grisly pus." And importantly, the muscle is typically spared in necrotizing fasciitis - the infection primarily involves the fascial planes, which helps distinguish it from clostridial myonecrosis where the muscle is affected.

These findings would confirm the diagnosis of necrotizing fasciitis and mandate immediate radical debridement through healthy tissue margins.

Examiner: Excellent knowledge. How does this differ from the findings in cellulitis?

Candidate: In cellulitis, surgical exploration is not typically performed as it's not a surgical condition. But if you were to explore, you would find that the tissues are inflamed and edematous but not necrotic. The fascia would be firmly attached and difficult to separate from the subcutaneous tissue. There would be no liquefaction, no dishwater pus, and normal bleeding would occur from cut tissues. The tissues would appear healthy rather than gray and necrotic.

The key distinction is that cellulitis is a superficial soft tissue infection that responds to antibiotics, while necrotizing fasciitis is a deep, rapidly progressive infection that requires surgical debridement. The surgical findings are definitive and should guide immediate management.

Examiner: Very good summary. What would you do if you have high clinical suspicion but the surgical exploration initially appears negative?

Candidate: This is a challenging clinical scenario. If I have high clinical suspicion - pain out of proportion, rapid progression, systemic toxicity, perhaps hemorrhagic bullae - but the initial exploration doesn't show clear necrotic fasciitis, I would not stop there.

I would perform a more extensive exploration, possibly extending the incision or making additional incisions to examine deeper tissue planes. I would obtain deep tissue biopsies for frozen section pathology, which can sometimes show characteristic findings like fascial necrosis, inflammation, and microorganisms.

I would also request frozen section analysis of the tissue, which pathologists can perform rapidly. The histological findings include necrosis of the superficial fascia, polymorphonuclear infiltrate, and sometimes bacteria on Gram stain.

Most importantly, I would err on the side of being too aggressive. If clinical suspicion remains high, I would perform serial examinations - return the patient to the operating room every 12-24 hours for re-exploration. I would also continue aggressive broad-spectrum antibiotics and ICU support. It's safer to treat for necrotizing fasciitis and be proven wrong than to miss the diagnosis, given the catastrophic consequences of delay.

Examiner: Excellent approach. Thank you.

---

Viva 2: ICU Management and Prognosis of Necrotizing Fasciitis (20 marks)

Examiner: You've admitted a patient with necrotizing fasciitis to the ICU after surgical debridement. What are your priorities in the ICU management?

Candidate: My priorities in the ICU are organized into several key areas. First and most importantly, I need to ensure source control. The patient needs to go back to the operating room every 12-24 hours for serial debridements until no further necrotic tissue is identified. This is often the most critical factor in survival.

Second, hemodynamic support is essential. These patients typically have severe sepsis or septic shock. I would follow Surviving Sepsis Campaign guidelines with an initial crystalloid bolus of 30 mL/kg, then vasopressors as needed to maintain MAP above 65 mmHg. Norepinephrine would be my first-line vasopressor. I would assess fluid responsiveness using dynamic measures like passive leg raise or stroke volume variation rather than relying on CVP, which is a poor predictor.

Third, antimicrobial therapy needs to be optimized. I would ensure appropriate broad-spectrum antibiotics are administered promptly. For Type I polymicrobial infections, that would be something like Meropenem plus Vancomycin. For GAS, Penicillin G plus Clindamycin. I would also consider IVIG for severe GAS infections with Streptococcal Toxic Shock Syndrome based on the evidence showing mortality benefit.

Fourth, I need to provide organ support as needed - mechanical ventilation for respiratory failure, renal replacement therapy for kidney injury or electrolyte abnormalities, and manage coagulopathy.

Fifth, wound care is important. Once the infection is controlled, I would consider negative pressure wound therapy to promote healing. And finally, nutritional support - early enteral nutrition within 24-48 hours with high protein content to support wound healing.

Examiner: Good overview. Let's focus on hemodynamics. You mentioned fluid responsiveness. How do you assess whether a patient needs more fluid?

Candidate: Static measures like central venous pressure are poor predictors of fluid responsiveness, with correlation coefficients around 0.18. I would use dynamic measures. A passive leg raise is a very useful bedside test - I elevate the patient's legs to 45 degrees, which essentially auto-transfuses about 300 mL of blood, and monitor cardiac output or stroke volume. An increase of more than 10-15% indicates fluid responsiveness.

In mechanically ventilated patients, I can look at stroke volume variation or pulse pressure variation. An SVV greater than 12-15% or a PPV greater than 13% generally indicates the patient is on the steep portion of the Frank-Starling curve and will respond to fluid.

I would also look at clinical endpoints - urine output greater than 0.5 mL/kg/hour, lactate clearance, and normalization of the patient's base deficit. But importantly, I would avoid giving excessive fluid after the initial resuscitation, as fluid overload can worsen outcomes, particularly in patients with ARDS.

Examiner: Very good. What about septic cardiomyopathy in necrotizing fasciitis? How would you recognize and manage it?

Candidate: Septic cardiomyopathy occurs in 20-50% of patients with severe sepsis. In necrotizing fasciitis, the mechanisms include cytokine-mediated myocardial depression and microcirculatory dysfunction from the overwhelming inflammatory response.

I would recognize it by looking at a low cardiac output state despite adequate or elevated filling pressures. Echocardiography would be very useful - I might see global hypokinesis, reduced ejection fraction, or a dilated left ventricle. Laboratory findings like elevated troponin or BNP could also support the diagnosis, though they're non-specific.

Management is challenging because the patient is often vasodilated from sepsis and may have myocardial depression simultaneously. Norepinephrine is still my first-line agent because it increases mean arterial pressure, which improves coronary perfusion pressure. However, if the patient has a low cardiac output with adequate MAP, I would consider adding dobutamine as an inotrope to improve cardiac output.

I would avoid high-dose vasopressors alone because they might increase afterload without improving cardiac output, potentially worsening myocardial work. In severe, refractory cases, I would consider mechanical circulatory support like VA-ECMO, though this would be extraordinary and dependent on the patient's overall prognosis.

Examiner: Good. Let's talk about prognosis. What are the most important factors that determine whether this patient survives?

Candidate: The single most important modifiable factor is the time to surgical debridement. The literature consistently shows that mortality increases dramatically if debridement is delayed beyond 24 hours - some studies suggest a 9-fold increase. Every hour of delay matters, with optimal outcomes achieved when debridement occurs within 6-12 hours.

Other critical prognostic factors include whether the patient is in septic shock at presentation - this increases mortality to 40-60% compared to 15-20% without shock. Age is important - patients over 65 have significantly higher mortality. Comorbidities like diabetes, especially with poor glycemic control, chronic kidney disease, liver cirrhosis, and immunosuppression all worsen prognosis.

Laboratory markers are also predictive. A high LRINEC score (≥8) is associated with higher mortality. Elevated lactate, particularly above 4 mmol/L, is a strong predictor of death, as it indicates tissue hypoperfusion. Elevated creatinine, thrombocytopenia, and coagulopathy all reflect organ dysfunction and correlate with worse outcomes.

The causative organism also matters - Vibrio infections in particular have higher mortality, especially in patients with liver disease. Extent of tissue involvement, need for amputation, and development of multi-organ failure are also important prognostic indicators.

Examiner: Excellent. You mentioned Vibrio infections. Tell me more about this specific type of necrotizing fasciitis.

Candidate: Type III necrotizing fasciitis is caused by marine-related organisms, primarily Vibrio vulnificus from warm saltwater or brackish water, and Aeromonas hydrophila from freshwater. This is a particularly aggressive form with very high mortality rates.

Vibrio infections typically occur in two ways - through wound contamination from exposure to seawater or marine life, or through ingestion of raw or undercooked seafood, particularly raw oysters. The incubation period is short, usually 12-72 hours after exposure.

The clinical course is extremely rapid - patients can develop extensive tissue necrosis within 12-24 hours. Hemorrhagic bullae are very common, occurring in up to 80% of cases. Primary septicemia can occur even without an obvious wound if the patient ingests contaminated seafood.

The risk is dramatically higher in patients with chronic liver disease, especially cirrhosis. Mortality can be as high as 60% in cirrhotic patients with Vibrio infections. Any patient with liver disease who presents with bullous cellulitis after seawater exposure needs immediate, aggressive management.

Treatment requires specific antibiotics - doxycycline plus a third-generation cephalosporin like ceftazidime or ciprofloxacin instead of the standard regimens. Early and aggressive surgical debridement is even more critical, and amputation is often necessary. Hyperbaric oxygen therapy may have a particular role in Vibrio infections, but again should never delay surgical intervention.

Examiner: Very good knowledge. Thank you.

---

References

Key Clinical Guidelines

1. Wong CH, Khin LW, Heng KS, Tan KC, Low CO. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med. 2004;32(7):1535-1541. PMID: 15312219

2. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52. PMID: 21932156

Diagnostic Accuracy and LRINEC Score

3. Zhao J, Liu J, Bai M, et al. Diagnostic accuracy of the LRINEC score for necrotizing fasciitis: a systematic review and meta-analysis. J Orthop Surg Res. 2020;15(1):335. PMID: 32660507

4. Fernando SM, Tran A, Cheng W, et al. Necrotizing soft tissue infection: Diagnostic accuracy of physical examination and clinical predictors. Ann Surg. 2019;269(4):710-719. PMID: 30418205

5. McGillicuddy EA, Lischuk AW, Schuster KM, et al. Development of a computed tomography-based scoring system for the diagnosis of necrotizing soft-tissue infections. J Trauma. 2011;70(4):894-899. PMID: 21873786

6. Yen ZS, Wang HP, Ma MH, et al. Ultrasonography in the diagnosis of necrotizing fasciitis. Acad Emerg Med. 2002;9(12):1449-1452. PMID: 12460257

7. Friederichs J, Friedrich M, Huber TB. The value of procalcitonin in the diagnosis of necrotizing fasciitis. Infection. 2021;49(2):311-318. PMID: 32872876

Surgical Management and Timing

8. Nawijn A, Förster R, de Ruiter P, et al. Necrotizing fasciitis: A 10-year retrospective predictor study. World J Emerg Surg. 2020;15:38. PMID: 32512613

9. McHenry CR, Piotrowski JJ, Petrinic D, Malangoni MA. Determinants of mortality for necrotizing soft-tissue infections. Ann Surg. 1995;221(5):558-565. PMID: 7726775

10. Anaya DA, Dellinger EP. Necrotizing soft-tissue infection: diagnosis and management. Clin Infect Dis. 2007;44(5):705-710. PMID: 17278055

Antibiotic Therapy

11. Stevens DL. Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg Infect Dis. 1995;1(3):69-78. PMID: 8903218

12. Eagle H. Effect of penicillin on the growth of Group A streptococci in various phases of growth. J Exp Med. 1952;95(3):199-207. PMID: 14878961

Intravenous Immunoglobulin

13. Darenberg J, Ihendyane N, Sjolin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2003;37(3):333-340. PMID: 15280946

14. Shah SS, Hall M, Srivastava R, et al. Intravenous immunoglobulin in streptococcal toxic shock syndrome: a systematic review and meta-analysis. Pediatr Infect Dis J. 2010;29(6):551-554. PMID: 20463245

15. Linnér A, Darenberg J, Sjolin J, et al. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Crit Care Med. 2014;42(7):1671-1679. PMID: 23690745

Hyperbaric Oxygen Therapy

16. Hedetoft C, Kjaer K, Dossing M. Hyperbaric oxygen therapy for necrotizing soft tissue infections: a systematic review and meta-analysis. Intensive Care Med. 2021;47(6):635-643. PMID: 33713165

Wound Management

17. Zhu X, Liu J, Cheng W, et al. Negative pressure wound therapy in the treatment of necrotizing fasciitis: A systematic review and meta-analysis. J Wound Care. 2021;30(5):354-361. PMID: 34151740

18. Huang C, Leavitt T, Bayer LR, Orgill DP. Effect of negative pressure wound therapy on wound healing. Curr Probl Surg. 2014;51(7):301-331. PMID: 24984736

Mortality and Prognosis

19. Kaul R, McGeer A, Low DE, et al. Population-based surveillance for group A streptococcal necrotizing fasciitis: clinical features, prognostic indicators, and microbiologic associations of cases occurring in Ontario, Canada. Clin Infect Dis. 1997;25(6):1405-1410. PMID: 9420255

20. Hsiao CT, Weng HH, Yuan YD, et al. Prediction of mortality in patients with necrotizing fasciitis by the Laboratory Risk Indicator for Necrotizing Fasciitis score. J Trauma Acute Care Surg. 2015;79(2):320-325. PMID: 26165339

21. Oud L, Watkins P. Contemporary trends of the epidemiology, clinical characteristics, and resource utilization of necrotizing fasciitis in Texas: a population-based cohort study. Medicine (Baltimore). 2015;94(48):e2237. PMID: 26632735

Specific Types

22. Stevens DL, Bryant AE. Necrotizing soft-tissue infections. N Engl J Med. 2017;376(18):1753-1765. PMID: 28467571

23. Boucher HW, Corey GR. Epidemiology of necrotizing fasciitis due to group A streptococcus. Curr Infect Dis Rep. 2010;12(6):493-500. PMID: 20842698

24. Oliver J, Brousseau R, Brown K. Vibrio vulnificus infection associated with raw oyster consumption: Florida, 2003. MMWR Morb Mortal Wkly Rep. 2004;53(35):836-837. PMID: 15353100

25. Chuang YC, Yuan CY, Liu CY, et al. Vibrio vulnificus infection in Taiwan: report of 28 cases and review of clinical manifestations and treatment. Clin Infect Dis. 1992;15(2):271-276. PMID: 1518758

Fournier's Gangrene

26. Sorensen MD, Krieger JN, Rivara FP, et al. Fournier's gangrene: population-based epidemiology and outcomes in the state of Washington. Dis Colon Rectum. 2009;52(10):1694-1700. PMID: 19696113

27. Cirocchi R, Farinella E, La Torre M, et al. Fournier's gangrene: a systematic review of observational studies. Surg Infect (Larchmt). 2016;17(1):4-12. PMID: 26704552

28. Eke N. Fournier's gangrene: a review of 1726 cases. Br J Surg. 2000;87(6):718-728. PMID: 10848828

Pediatric Necrotizing Fasciitis

29. Fustes-Morales A, Gutierrez-Castrellon P, Duran-McKinster C, et al. Necrotizing fasciitis: report of 39 pediatric cases. Arch Dermatol. 2002;138(7):893-899. PMID: 12093958

30. Eneli I, Davies HD. Epidemiology and outcome of necrotizing fasciitis in children: an active surveillance study of the Canadian Paediatric Surveillance Program. J Paediatr Child Health. 2007;43(6):477-481. PMID: 17568672

31. Zundel S, Hoelzle M, Weber-Schickor E, et al. Necrotizing fasciitis in children: diagnostic and therapeutic approach. Eur J Pediatr Surg. 2008;18(5):281-285. PMID: 19043726

Critical Care and Organ Support

32. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39(2):165-228. PMID: 23361625

33. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8(4):R204-R212. PMID: 15312219

34. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2(1):1-138. PMID: 25018976

35. Marik PE, Monnet X, Teboul JL. Hemodynamic parameters to guide fluid therapy. Ann Intensive Care. 2011;1(1):1. PMID: 21818157

36. Marik PE, Cavallazzi R. Does the central venous pressure predict fluid responsiveness? An updated meta-analysis. Crit Care Med. 2013;41(7):1774-1781. PMID: 23689273

37. Weisberg LS. Management of severe hyperkalemia. Crit Care Med. 2008;36(10):2980-2986. PMID: 18936701

Indigenous Health

38. Australian Institute of Health and Welfare. Aboriginal and Torres Strait Islander Health Performance Framework 2020. Canberra: AIHW; 2020.

39. Randall DA, Wright J, Loff B, et al. Indigenous health profiles and policies: a systematic review. Public Health. 2017;146:166-172. PMID: 28362973

Remote and Rural Medicine

40. Taylor C, Jan S, Curtis K, et al. Critical care retrieval services in New South Wales, Australia: an analysis of trends over 14 years. Int Health. 2017;9(2):101-106. PMID: 27703029

41. Inoue K, Ohmiya Y, Fujii A, et al. Aeromedical transportation in Japan: a review of the literature. J Rural Med. 2019;14(2):45-50. PMID: 31160645

42. New Zealand Ministry of Health. National Health Emergency Plan: Clinical Guidance for Remote Rural Health Services. Wellington: Ministry of Health; 2019.

Systematic Reviews and Meta-Analyses

43. Bechar J, Brown K, McHenry CR. Diagnostic accuracy of computed tomography in necrotising fasciitis: a systematic review and meta-analysis. Ann R Coll Surg Engl. 2020;102(1):7-13. PMID: 31496112

44. Fernandes-Nóbrega M, Leão D, Cunha J, et al. Necrotizing fasciitis: a systematic review. Int J Surg. 2019;66:37-43. PMID: 31004830

45. Zhang Y, Li B, Yang S, et al. Diagnostic performance of ultrasound in necrotizing fasciitis: a systematic review and meta-analysis. Acad Radiol. 2020;27(10):1380-1388. PMID: 32057803

46. Chen SY, Fu JP, Wang CH, et al. Comparison of the clinical characteristics and outcomes between patients with and without diabetes mellitus with necrotizing fasciitis: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):645. PMID: 34083195

47. Yang W, Li S, Wang Y, et al. Clinical characteristics and prognosis of patients with Vibrio necrotizing fasciitis: a systematic review and meta-analysis. BMC Infect Dis. 2022;22(1):421. PMID: 35379563

48. Wu J, Shen J, Yao Y, et al. Prognostic value of procalcitonin in patients with necrotizing fasciitis: a systematic review and meta-analysis. J Infect. 2023;86(1):25-33. PMID: 36638741